

Regimen Reference Order – CNS – lomustine

ARIA: CNS – [lomustine]

Planned Course: Every 42 days until disease progression or unacceptable toxicity

Indication for Use: Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – CNS – lomustine		
Drug	Dose	CCMB Administration Guideline
Day 1		
aprepitant	125 mg	Orally 1 hour pre chemotherapy (Self-administered at home)
ondansetron	16 mg	Orally 30 to 60 minutes pre chemotherapy (Self-administered at home)
lomustine	110 mg/m ²	Orally on an empty stomach at bedtime Swallow whole (Self-administered at home)
Day 2		
aprepitant	80 mg	Orally once in the morning (Self-administered at home)
ondansetron	8 mg	Orally once in the morning (Self-administered at home)
Day 3		
aprepitant	80 mg	Orally once in the morning (Self-administered at home)
lomustine (CeeNU®) available dosage strengths: 10 mg and 40 mg capsules Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, electrolytes, liver enzymes, total bilirubin and albumin as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	20 mg	Orally every 4 hours as needed for nausea and vomiting

INSTRUCTIONS FOR PATIENT

- Reinforce applicable safe handling precautions of medications, blood and body fluids while on temozolomide
- lomustine can rarely cause pulmonary fibrosis. Patients should report any signs of respiratory complications

ADDITIONAL INFORMATION

- All oral agents as part of this regimen (lomustine, aprepitant, ondansetron, metoclopramide) will be dispensed by CancerCare Manitoba Pharmacy